[Image: Jafron logo]
Health Technology for a Better World
Stock Code: 300529.SZ
[Image: Jafron headquarters and medical technology graphic]
2025 Environmental, Social and Governance (ESG) Report
Tel.: 0756-3619693
Website: www.jafron.com
Email: ir@jafron.com
Address: 98 Keji 6th Road, Zhuhai National High-tech Industrial Development Zone, Zhuhai City, Guangdong, China
Table of Contents
About this Report 01
Message from the Chairman 03
About Us 05
Annual Thematic Initiative: "Love Life, Love Life More" – 919 Uremia Awareness Day 23
Sustainable Development Governance
Governance Framework for Sustainable Development 25
Communications with Stakeholders 26
Management of Material Topics 27
[Chart: Driving Industry Transformation through Innovation and Collaboration]
Innovation-Driven Development 31
Safety and Quality of Products and Services 42
Customer Service 48
Information Security and Data Protection 50
Responsible Supply Chain 53
[Chart: Consolidating the Foundation for Sustainable Development through Steadfast Governance]
Governance 61
Investor Relations Management and Shareholders’ Rights and Interests 64
Compliant Operation and Risk Management 66
Business Ethics 68
[Chart: Advancing Green Transformation to Enable Sustainable Healthcare]
Response to Climate Change 71
Environmental Compliance Management 74
Resource Utilization 79
Ecosystem and Biodiversity Protection 84
[Chart: Building a Harmonious Workplace through People-Oriented Development]
Protection of Employees' Rights and Interests 87
Training and Development 93
Occupational Health and Safety 97
Social Contribution 104
Appendix
Indexes 108
Key Performance Form 109
Feedback Form 118
About this Report
This is the second Environmental, Social and Governance (ESG) Report published by Jafron Biomedical Co., Ltd. (“Jafron”, the “Company” or “we”). In the principles of objectivity, standardization, transparency, and comprehensiveness, the Report provides a detailed disclosure of the Company's practices and performance in environmental, social, and governance for the year 2025.
Reporting Scope
This report covers Jafron and its subsidiaries. Unless otherwise stated, the scope of this report is consistent with the scope of the Company's Annual Report.
Reporting Period
This report covers the period from January 1, 2025 to December 31, 2025 (the "Reporting Period"). To improve the comparability and completeness, some sections of this report may be appropriately referred to previous years or contains forward-looking statements.
Preparation Basis
-
Shenzhen Stock Exchange Self-Regulatory Guidelines No. 17 for Companies Listed on Shenzhen Stock Exchange—Sustainability Report (For Trial Implementation)
-
Shenzhen Stock Exchange Self-Regulatory Guidelines No. 3 for Listed Companies on the Shenzhen Stock Exchange - Preparation of Sustainability Reports
-
Global Reporting Initiative Sustainability Reporting Standards (GRI Standards)
-
China Enterprise Reform and Development Society Guide to Corporate Sustainability Reporting in China (CASS-ESG 6.0)
-
Task Force on Climate-related Financial Disclosures (TCFD) Recommendations
-
United Nations Sustainable Development Goals (SDGs)
-
Sustainability Accounting Standards Board (SASB) Standards
Data Source
All information and data cited hereunder are sourced from Jafron's official documents, statistical reports and financial reports, as well as the sustainable development information collected, summarized and reviewed by all functional departments and business units of the Company. The Company guarantees that this report doesn't contain any false records, misleading statements, or material omissions. Unless otherwise specified, all amounts in this report are expressed in RMB.
Appellation Description
| Term | Definition |
|---|---|
| Jafron, the Company, we | Jafron Biomedical Co., Ltd. |
| Beijing Jafron | Beijing Jafron Medical Equipment Co Ltd. |
| Hubei Jafron | Hubei Jafron Biotechnology Co., Ltd. |
| Jianfu Pharmaceutical | Zhuhai Jianfu Pharmaceutical Co., Ltd. |
Confirmation and Approval
This report was approved by the Board of Directors of the Company for publication on April 27, 2026. The Board pledges to exercise oversight over the contents of this report, ensuring its absence of any false records or misleading representations, and assuming responsibility for its truthfulness, accuracy and completeness.